Clinical trials: Subcutaneous Injections
HIV Infections
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an antiretroviral drug.
- Trial name
- NCT00050856
- Testing
- Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastroenteropancreatic Neuroendocrine Tumor
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.
- Trial name
- PALACE (NCT04852679)
- Testing
- Lanreotide autogel
- Where
- 14 sites in China
- Volunteers
- 43 people
- Sponsor
- Ipsen
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices
- Trial name
- NCT01817569
- Where
- 46 sites in Japan
- Volunteers
- 2,948 people
- Sponsor
- AstraZeneca
Diabetes
CSII Pilot in Adolescents With Type 2 Diabetes
This feasibility pilot is intended to understand whether adolescents with Type 2 Diabetes (2DM) can be transitioned to a continuous subcutaneous insulin injection (CSII) and if so, assess whether CSII is a feasible treatment…
- Trial name
- NCT02748122
- Testing
- MMT 723
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting…
- Trial name
- PERFECT (NCT03347370)
- Testing
- SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b
- Where
- Germany
- Volunteers
- 626 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type 2 Diabetes
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.
- Trial name
- NCT06439056
- Testing
- NEX-22A, a prolonged release formulation of liraglutide
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Nanexa AB
Multiple Sclerosis
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
- Trial name
- NCT00207727
- Testing
- CNTO 1275
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Healthy Volunteers
SAD and MAD Study of FTX-101 in Healthy Male Subjects
This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects.
- Trial name
- NCT06617546
- Testing
- FTX-101
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Find Therapeutics
Safety, Pharmacokinetics
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
- Conditions
- Safety, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT02601625
- Testing
- Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®
To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.
- Trial name
- NCT01145950
- Testing
- LBEC0101, Enbrel
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences